Systematic review and meta-analysis for thrombolysis treatment in patients with acute submassive pulmonary embolism

Patient Preference and Adherence

Volumn 8, Issue , 2014, Pages 275-282

  Cao, Yaoqian ^a   Zhao, Haiyan ^a   Gao, Wanpeng ^a   Wang, Yan ^a   Cao, Jie ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Heparin; Pulmonary embolism; Submassive pulmonary embolism; Thrombolysis treatment; Warfarin

Indexed keywords

ALTEPLASE; HEPARIN; PLASMINOGEN ACTIVATOR; PROUROKINASE; STREPTOKINASE; TENECTEPLASE; UROKINASE;

BLOOD CLOT LYSIS; BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HEART RIGHT VENTRICLE FUNCTION; HUMAN; LUNG ANGIOGRAPHY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; MULTIDETECTOR COMPUTED TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; VALIDITY;

EID: 84897850838     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S56280     Document Type: Review

References (54)

1. Stein PD, Matta F. Epidemiology and incidence: the scope of the problem and risk factors for development of venous thromboembolism. Crit Care Clin. 2011;27(4):907-932.
2. Stein PD, Matta F, Keyes DC, Willyerd GL. Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism. Am J Med. 2012;125(5):478-484.
3. Stein PD, Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. Am J Med. 2012;125(5):465-470.
4. Stein PD, Matta F. Case fatality rate with pulmonary embolectomy for acute pulmonary embolism. Am J Med. 2012;125(5):471-477.
5. Kearon C, Akl EA, Comerota AJ, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2):e419S-e494S.
6. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993;341(8844): 507-511.
7. Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, Johnsson H, Jorfeldt L. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J. 1997;134(3): 479-487.
8. Grifoni S, Olivotto I, Cecchini P, et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation. 2000;101(24):2817-2822.
9. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(Suppl 6):454S-545S.
10. British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax. 2003;58(6):470-483.
11. Piazza G, Goldhaber SZ. Management of submassive pulmonary embolism. Circulation. 2010;122(11):1124-1129.
12. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
13. Miller GA, Sutton GC, Kerr IH, Gibson RV, Honey M. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Med J. 1971;2(5763):681-684.
14. Bell WR, Simon TL, Stengle JM, Sherry S. The urokinase-streptokinase pulmonary embolism trial (phase II) results. Circulation. 1974;50(6): 1070-1071.
15. Sasahra AA, Bell WR, Simon TL, Stengle JM, Sherry S. The phase II urokinase-streptokinase pulmonary embolism trial: a national cooperative study. Thromb Diath Haemorrh. 1975;33(3):464-476.
16. Bell WR. Streptokinase and urokinase in the treatment of pulmonary thromboemboli; from a national cooperative study. Thromb Haemost. 1976;35(1):57-69.
17. Charbonnier B. [Multicenter study of 2 urokinase protocols in severe pulmonary embolism. Research Group on Urokinase and Pulmonary Embolism]. Arch Mal Coeur Vaiss. 1984;77(7):773-781. French [with English abstract].
18. Giuntini C, Marini C, Di Ricco G, Palla R, Giacomelli V, Rindi M. A controlled clinical trial on the effect of heparin infusion and two regimens of urokinase in acute pulmonary embolism. G Ital Cardiol. 1984;14 Suppl 1:26-29.
19. François G, Charbonnier B, Raynaud P, Garnier LF, Griguer P, Brochier M. [Treatment of acute pulmonary embolism with urokinase compared with the combination plasminogen-urokinase. Apropos of 67 cases]. Archives des Maladies du Coeur et des Vaisseaux. 1986;79(4):435-442. French [with English abstract].
20. Goldhaber SZ, Kessler CM, Heit J, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet. 1988;2(8606): 293-298.
21. Sasahara AA, Henkin J, Janicki RS, et al. Urokinase versus tissue plasminogen activator in pulmonary embolism. Lancet. 1988;2(8612): 691-692.
22. Verstraete M, Miller GA, Bounameaux H, et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation. 1988;77(2):353-360.
23. Goldhaber SZ. TPA versus urokinase in acute pulmonary embolism: results of a randomized controlled trial. Vasa Suppl. 1989;27:292-294.
24. Goldhaber SZ, Kessler CM, Heit JA, et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol. 1992;20(1):24-30.
25. Meyer G, Sors H, Charbonnier B, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. J Am Coll Cardiol. 1992;19(2):239-245.
26. Sors H, Pacouret G, Azarian R, Meyer G, Charbonnier B, Simonneau G. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest. 1994;106(3):712-717.
27. Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. Chest. 1994;106(3):718-724.
28. Agnelli G, Iorio A, Parise P, Goldhaber SZ, Levine MN. Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group. Blood Coagul Fibrinolysis. 1997;8(4):216-222.
29. Meneveau N, Schiele F, Vuillemenot A, et al. Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. Eur Heart J. 1997;18(7):1141-1148.
30. Meneveau N, Schiele F, Metz D, et al. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. J Am Coll Cardiol. 1998;31(5):1057-1063.
31. Tebbe U, Graf A, Kamke W, et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J. 1999;138(1):39-44.
32. Wang C, Zhai Z, Yang Y, et al; China Venous Thromboembolism Study Group. Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: a randomized controlled trial. Respir Res. 2009;10(1):128.
33. Wang C, Zhai Z, Yang Y, et al; China Venous Thromboembolism (VTE) Study Group. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest. 2010;137(2):254-262.
34. Wu YQ, Tao LB, Lü C, Hu YH. [An economic evaluation of low dose recombinant human tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism]. Zhonghua Yi Xue Za Zhi. 2010;90(2):103-106. Chinese [with English abstract].
35. Abdelsamad AA, El-Morsi AS, Mansour AE. Efficacy and safety of high dose versus low dose streptokinase for treatment of submassive pulmonary embolism. The Egyptian Heart Journal. 2011;63(2):67-72.
36. Yang Y, Wang Y, Ma Z, et al. Efficacy and safety of two-hour regimen of recombinant streptokinase versus urokinase in massive and submassive pulmonary embolism: A randomized controlled trial. Respirology. 2011;16:309.
37. Elliot MS, Immelman EJ, Jeffery P, et al. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial. Br J Surg. 1979;66(12):838-843.
38. Dotter CT, Seaman AJ, Rösch J, Porter JM. Streptokinase and heparin in the treatment of pulmonary embolism: a randomized comparison. Vascular and Endovascular Surgery. 1979;13(1):42-52.
39. Sharma GVRK, Burleson VA, Sasahara AA. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. N Engl J Med. 1980;303(15):842-845.
40. Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest. 1990;98(6):1473-1479.
41. Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators. Chest. 1990;97(3):528-533.
42. Dalla-Volta S, Palla A, Santolicandro A, et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol. 1992;20(3):520-526.
43. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002;347(15):1143-1150.
44. Becattini C, Agnelli G, Salvi A, et al; TIPES Study Group. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res. 2010;125(3): e82-e86.
45. Fasullo S, Scalzo S, Maringhini G, et al. Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin. Am J Med Sci. 2011;341(1):33-39.
46. Thabut G, Thabut D, Myers RP, et al. Thrombolytic therapy of pulmonary embolism: a meta-analysis. J Am Coll Cardiol. 2002;40(9): 1660-1667.
47. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation. 2004;110(6): 744-749.
48. Konstantinides S. Clinical practice. Acute pulmonary embolism. N Engl J Med. 2008;359(26):2804-2813.
49. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353(9162):1386-1389.
50. Ucar EY, Araz O, Akgun M, et al. Low-molecular-weight heparin use with thrombolysis: is it effective and safe? Ten years' clinical experience. Respiration. 2013;86(4):318-323.
51. Riera-Mestre A, Jiménez D, Muriel A, et al; RIETE investigators. Thrombolytic therapy and outcome of patients with an acute symptomatic pulmonary embolism. J Thromb Haemost. 2012;10(5):751-759.
52. Hamel E, Pacouret G, Vincentelli D, et al. Thrombolysis or heparin therapy in massive pulmonary embolism with right ventricular dilatation: results from a 128-patient monocenter registry. Chest. 2001;120(1): 120-125.
53. Konstantinides S, Marder VJ. Thrombolysis in venous thromboembolic disease. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, editors. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:1317-1329.
54. Assistance Publique, Hôpitaux de Paris. PEITHO pulmonary embolism thrombolysis study. Available from http://clinicaltrials.gov/ct2/show/NCT00639743?term=PEITHO+pulmonary+embogov/ct2/show/NCT00639743?term=PEITHO+pulmonary+embolism+thrombolysis+study&rank=1. NLM identifier: NCT00639743. Accessed December 21, 2011.